|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A previous study by our group revealed that decreased expression of a tumor suppressor-AXIN2 (Axis inhibition protein 2) was responsible for enhanced PASMC proliferation and suppressed apoptosis.
|
28694128 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LL-37 treatment of tumor cells also decreased the levels of Axin2.
|
31149039 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rates of tumor growth inhibition showed good correlation with the behavior of pharmacodynamic biomarkers, such as Axin2 accumulation and MYC downregulation.
|
30238564 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, Axin2 may serve as either a promoter or suppressor of tumors, and the effects of its inhibition on the cell proliferation and metastasis of CRC require further elucidation.
|
29534875 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Depletion of MEIS1 and MEIS2 resulted in increased tumor growth over time <i>in vivo</i>, and decreased MEIS expression in both patient-derived tumors and MEIS-depleted cell lines was associated with increased expression of the protumorigenic genes cMYC and CD142, and decreased expression of AXIN2, FN1, ROCK1, SERPINE2, SNAI2, and TGFβ2.<b>Conclusions:</b> These data implicate a functional role for MEIS proteins in regulating cancer progression, and support a hypothesis whereby tumor expression of MEIS1 and MEIS2 expression confers a more indolent prostate cancer phenotype, with a decreased propensity for metastatic progression.<i></i>.
|
29716922 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear accumulation of β-Catenin, increased expression of Cyclin D1 and significantly higher expression of AXIN2 (p = 0.0039), ZNRF3 (p = 0.0032) and LEF1(p = 0.0090) observed in the tumours harbouring the deletion in comparison to tumours without CTNNB1 mutation demonstrates that the truncated β-Catenin is functionally active and erroneously activates the downstream targets.
|
29872083 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To elucidate potential roles of Wnt/β-catenin signal-associated gene methylation in GNCCP, we performed β-catenin immunostaining and methylation-specific polymerase chain reaction (PCR) for their associated genes, including SFRPs, APC, AXIN2, and MCC, in 26 GNCCPs [i.e., 11 intramucosal (GNCCP-Ms) and 15 submucosal tumors (GNCCP-SMs)], and compared with 27 fundic gland polyps (FGPs), 12 FGPs with dysplasia (FGP-Ds), 27 conventional gastric adenocarcinomas (CGAs).
|
28105693 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Axis inhibition protein2 ( Axin2), a major scaffold protein is an antagonist of Wnt pathway and is potent to act as a tumor suppressor gene in various human cancers.
|
28378643 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
β-catenin downregulation and tumor growth inhibition was associated with reduction in AXIN2, direct transcriptional target of β-catenin, and decreased cancer cell proliferation as measured by Ki67 staining.
|
29383099 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a significant overexpression of AXIN2 in WTs (P < 0.0001), with 33 (32 %) tumors showing higher expression (median + 3× SD) than normal kidney tissue.
|
27679509 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
|
26771938 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, reprogrammed tumors enhance GLI2, and we show that GLI2(high) and AXIN2(low), which are markers of the metastatic transition of colon cancers, are prognostic of poor disease outcome in patients.
|
26031752 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GLI1 and AXIN2 were upregulated in the primary tumor and in two inoculation metastases compared to normal brain.
|
27825128 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An AXIN2 Mutant Allele Associated With Predisposition to Colorectal Neoplasia Has Context-Dependent Effects on AXIN2 Protein Function.
|
26025668 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We further demonstrate that in vivo, LY2090314 elevates Axin2 gene expression after a single dose and produces tumor growth delay in A375 melanoma xenografts with repeat dosing.
|
25915038 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Axin2, a tumor suppressor, exhibited a marked inhibitory effect on Eca109 cell growth.
|
26252180 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, WNT/β-catenin signal activation mediated by the methylation of SFRP4, MCC, and AXIN2 may make different contributions to colorectal neoplasia between the serrated and conventional routes.
|
24925057 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Axis inhibition protein 2 (Axin2) is a negative regulator of the canonical Wnt/β-catenin signaling pathway, and functions as a tumor suppressor in a number of human cancers.
|
25091576 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/β-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels.
|
24166495 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The previously described AXIN2 in-frame heterozygous 12bp deletion c2013_2024del12 was found in 1 of the 49 ACC studied (2%), in a tumor with pSer45del activating CTNNB1 mutation and nuclear β-catenin staining.
|
23812285 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functionally, the β-catenin-Axin2-Snail cascade is required for Kindlin 2-induced tumour cell invasion.
|
22699938 |
2012 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Promoter methylation of Axin2 and APC genes was detected in 7.1 and 11.9% of tumors, respectively.
|
22207181 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our report provides additional evidence supporting an autosomal dominant AXIN2-associated ectodermal dysplasia and neoplastic syndrome.
|
21416598 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The objective of the study was to investigate whether alterations in AXIN2 may be present in adrenocortical tumors.
|
21733995 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both AXIN2 and TCF7L2 genes in the Wnt pathway possess mononucleotide repeats in their coding sequences and are considered as candidate tumor suppressor genes.
|
18755497 |
2009 |